Figure 1.
mm-SW in CD371pos BCP-ALL by flow cytometry. With the beginning of steroid treatment as per AIEOP-BFM ALL 2009 protocol, residual lymphoblastic cells showed an mm-SW. It displayed 2 different patterns: (A) a single population of blast cells with heterogeneous expression of CD19 (1-population pattern: orange population); and (B) a 2-population pattern: the first population keeping the immunophenotype of the diagnosis (blue population); the second population showing a downregulation of CD19 and CD34, an upregulation of CD45, and an increase of SSC (orange population). Technical information: fluorochromes: CD19-PC7, CD10-APC/ALEXA700, CD20- V450, CD34-APC, CD58-FITC, CD371-PC5.5, and CD45-V500; sample preparation and acquisition at ambient temperature; sample acquisition: Navios Flow Cytometer (Beckman Coulter, Inc); sample analysis: Software Kaluza 2.1 (Beckman Coulter, Inc). Please see supplemental Data for additional information.

mm-SW in CD371pos BCP-ALL by flow cytometry. With the beginning of steroid treatment as per AIEOP-BFM ALL 2009 protocol, residual lymphoblastic cells showed an mm-SW. It displayed 2 different patterns: (A) a single population of blast cells with heterogeneous expression of CD19 (1-population pattern: orange population); and (B) a 2-population pattern: the first population keeping the immunophenotype of the diagnosis (blue population); the second population showing a downregulation of CD19 and CD34, an upregulation of CD45, and an increase of SSC (orange population). Technical information: fluorochromes: CD19-PC7, CD10-APC/ALEXA700, CD20- V450, CD34-APC, CD58-FITC, CD371-PC5.5, and CD45-V500; sample preparation and acquisition at ambient temperature; sample acquisition: Navios Flow Cytometer (Beckman Coulter, Inc); sample analysis: Software Kaluza 2.1 (Beckman Coulter, Inc). Please see supplemental Data for additional information.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal